Edition:
India

Sientra Inc (SIEN.OQ)

SIEN.OQ on NASDAQ Stock Exchange Global Select Market

11.13USD
16 Feb 2018
Change (% chg)

$-0.10 (-0.89%)
Prev Close
$11.23
Open
$11.24
Day's High
$11.27
Day's Low
$11.03
Volume
43,556
Avg. Vol
59,722
52-wk High
$16.61
52-wk Low
$7.21

Latest Key Developments (Source: Significant Developments)

Sientra Provides Update On FDA Review Of U.S. Manufacturing Facility
Wednesday, 31 Jan 2018 

Jan 30 (Reuters) - Sientra Inc ::SIENTRA® PROVIDES UPDATE ON FDA REVIEW OF U.S. MANUFACTURING FACILITY.SIENTRA INC - ‍FDA GRANTED APPROVAL OF SITE-CHANGE PMA SUPPLEMENT FOR CONTRACT MANUFACTURER TO MANUFACTURE CO'S SILICONE GEL BREAST IMPLANTS​.  Full Article

Sientra Announces Preliminary Unaudited Q4 Revenue
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sientra Inc ::SIENTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER 2017 REVENUE.SEES Q4 2017 REVENUE ABOUT $11.4 MILLION.Q4 REVENUE VIEW $11.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Sientra Inc Files For Mixed Shelf Of Upto $150 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sientra Inc ::SIENTRA INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Sientra posts qtrly loss of $0.74​ per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Sientra Inc :Sientra reports third quarter 2017 financial results.Total net sales for Q3 2017 were $9.8 million, compared to total net sales of $6.5 million for same period in 2016​.Qtrly ‍basic and diluted net loss per share attributable to common stockholders $0.74​.Net cash and cash equivalents as of September 30, 2017 were $37.6 million compared to $55.5 million at end of Q2 2017​.  Full Article

Sientra Q2 loss per share $0.56
Tuesday, 9 Aug 2016 

Sientra Inc : Q2 sales $6.2 million versus $14.2 million . sientra® reports second quarter 2016 financial results and progress on manufacturing solution .Qtrly loss per share $0.56.  Full Article

Sientra updates on manufacturing solution
Tuesday, 9 Aug 2016 

Sientra Inc : Sientra provides update on manufacturing solution . Vesta establishing manufacturing capacity for sientra,working with co to finalize supply arrangement for pma-approved breast implants . Entered into a services agreement with Vesta, a lubrizol lifesciences company .Anticipates that all project milestones will be achieved for company to submit a pma supplement to fda during q1 of 2017.  Full Article

Sientra Inc acquires bioCorneum advanced silicone gel scar management therapy
Thursday, 10 Mar 2016 

Sientra Inc:Acquires bioCorneum advanced silicone gel scar management therapy.Says acquisition from Enaltus, LLC of the exclusive U.S. rights to bioCorneum®, an advanced silicone gel scar management products, for $7.0 million in cash.Under terms of the agreement, Sientra paid $7.0 million in an all cash transaction to acquire all of Enaltus's scar management assets for the professional channel, including exclusive U.S. distribution rights for bioCorneum.Sientra will retain seven specialty sales representatives from bioCorneum who will remain exclusively focused on the brand's expansion.  Full Article

BRIEF-Sientra Provides Update On FDA Review Of U.S. Manufacturing Facility

* SIENTRA® PROVIDES UPDATE ON FDA REVIEW OF U.S. MANUFACTURING FACILITY